# US 2010/0152109 A1 · Influenza inhibiting compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0152109 A1
- Document ID: US20100152109A1
- Status: Published application
- Kind: A1
- Application number: 12/452,240
- Filed: 2008-06-25
- Published: 2010-06-17
- Earliest claimed: 2007-06-25
- Assignees: The Administrators of the Tulane Educational Fund; Autoimmune Technologies, LLC
- Inventors: Robert F. Garry; Russell B. Wilson
- Web page: https://patentgrep.com/patent/US20100152109A1

## CPC

- C07K 14/005: from viruses
- A61K 38/04: Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55})
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61P 31/12: Antivirals
- A61P 31/16: for influenza or rhinoviruses
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 2760/00033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR.

## Claims

### Claim 1

An isolated peptide consisting of 8 to 40 consecutive amino acid residues of a portion of a selected wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the selected hemagglutinin 2 protein comprising the fusion initiation region (FIR) of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR and including at least the sequence YNAELL (SEQ ID NO: 1) or a variant thereof that differs from SEQ ID NO: 1 by one or more amino acid substitutions selected from the group consisting of Y1S, Y1T, Y1W, Y1A, N2Q, A3L, A3I, A3V, E4D, E4K, E4R, E4H, L5I, L5V, L5A, L6I, L6V, and L6A;
the amino acid sequence of the FIR comprising that portion of the selected wild-type hemagglutinin 2 (HA2) protein beginning at about residue 77 in the N-helix of the protein, and ending at a residue in the range of residue 110 to residue 119 of the selected wild-type hemagglutinin 2 protein, the carboxy-terminus of the FIR being the residue immediately preceding the first residue beginning a region of increasing Wimley-White interfacial hydrophobicity beyond residue 104 of the wild-type sequence;
the variant differing from the selected wild-type protein by one or more amino acid substitutions in the amino acid sequence of the portion of the selected wild-type protein; the substitutions being selected from corresponding amino acid residues of other wild-type influenza HA2 proteins, and preferably being selected so as to maintain a Wimley-White interfacial hydropathy profile for the variant having local maxima and local minima within about 5 amino acid residues of the local maxima and local minima of the Wimley-White interfacial hydropathy profile of the corresponding region of at least one wild-type HA2 protein.

### Claim 2 (depends on 1)

The isolated peptide of claim 1 wherein the wild-type influenza hemagglutinin 2 protein is selected from the group consisting of influenza A HA2 subtypes H1, H2, H3, H4, H5, H6, H7, H9, H10, H13, H14, H15 and H16.

### Claim 3 (depends on 1)

The isolated peptide of claim 1 wherein the wild-type influenza hemagglutinin 2 protein is an influenza B HA2 protein.

### Claim 4 (depends on 1)

The isolated peptide of claim 1, wherein the portion of the hemagglutinin 2 protein consists of residues 72 to 113 of the selected wild-type HA2 protein.

### Claim 5 (depends on 1)

The isolated peptide of claim 1, wherein the peptide consists of 8 to 40 consecutive amino acid residues of SEQ ID NO: 2 (EVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDS) or a variant thereof, the variant differing from SEQ ID NO: 2 by one or more amino acid substitutions;
wherein the peptide comprises at least amino acid residues 23 to 28 of SEQ ID NO: 2 or of the variant thereof; and wherein the one or more amino acid residue substitutions are selected from the group consisting of: E1D, E1N, E1Q, V2G, V2S, V2T, V2I, V2L, V2A, V2M, V2C, E3D, E3N, E3Q, G4T, G4S, G4K, G4R, G4H, G4Q, G4N, R5K, R5H, R5Q, R5N, I6L, I6V, I6A, I6M, I6C, Q7N, Q7E, Q7D, Q7G, Q7S, Q7T, D8E, D8N, D8Q, D8M, D8C, L9I, L9V, L9A, L9M, L9C, E10D, E10N, E10Q, E10I, E10L, E10V, E10A, E10M, E10C, K11R, K11H, K11D, K11E, K11N, K11Q, Y12W, Y12K, Y12R, Y12H, V13I, V13L, V13A, V13G, V13T, V13S, V13M, V13C, E14D, E14K, E14R, E14H, D15E, D15R, D15N, D15Q, T16G, T16S, T16A, T16Q, T16N, K17F, K17R, K17M, K17C, K17I, K17V, K17L, K17A, I18L, I18V, I18A, I18T, I18S, I18G, I18Q, I18N, D19E, D19N, D19Q, L20I, L20V, L20A, L20C, L20M, W21Y, W21A, S22T, S22G, S22A, S22M, S22C, Y23W, Y23S, Y23T, Y23A, N24Q, N24D, N24E, A25I, A25V, A25L, A25M, E26D, E26K, E26R, E26H, L27A, L27I, L27V, L27M, L28I, L28V, L28A, L28M, V291, V29L, V29A, V29M, A301, A30L, A30V, A30M, A30C, L31I, L31V, L31A, L31M, L31C, E32D, E32N, E32Q, N33Q, N33Q, Q34E, N33E, Q34E, Q34D, Q34G, Q34S, Q34T, H35K, H35R, H35N, H35Q, T36S, T36G, I37L, I37V, I37A, I37M, I37C, D38E, D38N, D38Q, L39F, L391, L39V, L39M, L39C, L39A, L39E, L39D, L39N, L39Q, T40H, T40R, T40K, T40S, T40G, T40A, T40M, D41E, D41N, D41Q, S42G, S42T, S42I, S42L, S42V, S42A, S42M, and S42C.

### Claim 6 (depends on 1)

The isolated peptide of claim 1, wherein the variant shares at least 50 percent sequence identity with SEQ ID NO: 2.

### Claim 7 (depends on 1)

The isolated peptide of claim 1, wherein the variant shares at least 60 percent sequence identity with SEQ ID NO: 2.

### Claim 8 (depends on 1)

The isolated peptide of claim 1, wherein the variant shares at least 70 percent sequence identity with SEQ ID NO: 2.

### Claim 9 (depends on 1)

The isolated peptide of claim 1, wherein the variant shares at least 80 percent sequence identity with SEQ ID NO: 2.

### Claim 10 (depends on 5)

The isolated peptide of claim 5, wherein the variant of SEQ ID NO: 2 includes the substitution E26K.

### Claim 11 (depends on 1)

The isolated peptide of claim 1, wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13.

### Claim 12 (depends on 1)

An analog of the peptide of claim 1, wherein the analog comprises at least one of the following modifications:
(a) a cyclic peptide structure including at least two cysteine residues forming a disulfide bridge, each cysteine residue independently being a residue of peptide, a residue bound to the amino-terminus of the peptide, or a residue bound to the carboxy-terminus or the peptide;
(b) a substitution of a non-natural amino acid residue at a peptidase cleavage site of the peptide;
(c) one or more proline residues replacing a residue within the peptide sequence; or
(d) one or more glycine residues replacing a residue within the peptide sequence.

### Claim 13 (depends on 12)

The analog of claim 12, wherein the non-natural amino acid residue is a D-amino acid.

### Claim 14 (depends on 1)

A derivative of the peptide of claim 1, wherein the peptide or analog includes a non-HA2-derived group bound to the peptide.

### Claim 15 (depends on 14)

The derivative of claim 14, wherein the non-HA2-derived group comprises at least one of the following groups:
(a) a lipid bound to a residue of the peptide;
(b) a polyethylene glycol group bond to a residue of the peptide; or
(c) a non-HA2 peptide sequence bound to the amino-terminus, the carboxy-terminus, or both termini of the peptide.

### Claim 16 (depends on 1)

An isolated antibody that is selective for the peptide, of claim 1.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising a peptide, of claim 1 in a pharmaceutically acceptable carrier.

### Claim at position 18

18-20. (canceled)

### Claim 21 (depends on 17)

A method of treating an influenza infection comprising administering to a subject suffering from influenza an influenza inhibiting amount of pharmaceutical composition of claim 17.

### Claim 22 (depends on 21)

The method of claim 21, wherein the subject suffers from an influenza A subtype H1, H3, or H5 infection.

### Claim 23 (depends on 21)

The method of claim 21, wherein the subject suffers from an influenza B infection.

### Claim 24 (depends on 17)

A method for preventing transmission of an influenza infection from an influenza infected to a non-infected subject, the method comprising administering to the subject suffering from influenza an influenza inhibiting amount of pharmaceutical composition of claim 17.

### Claim 25 (depends on 24)

The method of claim 24, wherein the influenza infected subject suffers from an influenza A subtype H1, H3, or H5 infection.

### Claim 26 (depends on 24)

The method of claim 24 wherein the influenza infected subject suffers from an influenza B infection.

### Claim 27 (depends on 17)

A method for preventing an influenza infection in a subject, the method comprising administering to the subject an influenza inhibiting amount of pharmaceutical composition of claim 17.

### Claim 28 (depends on 27)

The method of claim 27, wherein the influenza infection is an influenza A subtype H1, H3, or H5 infection.

### Claim 29 (depends on 27)

The method of claim 27, wherein the influenza infection is an influenza B infection.

### Claim 30 (depends on 21)

The method of claim 21, wherein the administering comprises intranasal administration of the pharmaceutical composition.

### Claim 31 (depends on 24)

The method of claim 24, wherein the administering comprises intranasal administration of the pharmaceutical composition.

### Claim 32 (depends on 27)

The method of claim 27, wherein the administering comprises intranasal administration of the pharmaceutical composition.

### Claim 33 (depends on 21)

The method of claim 21, wherein the amino and sequence pharmaceutical composition comprises a peptide selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13.
